酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理中国专家共识(2022版)

Chinese expert consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumor(2022 edition)

酪氨酸激酶抑制剂(TKIs)可显著提高胃肠间质瘤(GIST)患者总生存率,但不良反应会影响用药剂量及患者治疗依从性,进而影响临床疗效。2018年,中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会组织涉及GIST靶向药物治疗不良反应相关的临床科室专家,基于临床证据和经验形成我国首部《酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理共识》。随着TKIs临床应用的普及和对其不良反应认识的加深,尤其是近年来新型TKIs药物加入GIST治疗药物管线,中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会再次组织专家经修订、更新形成《酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理中国专家共识(2022版)》,以期指导临床实践中对TKIs不良反应的预警和处理。

Tyrosine kinase inhibitors(TKIs)can significantly improve the overall survival rate of patients with gastrointestinal stromal tumor(GIST),but the side effects affect the dose intensity and treatment compliance of patients,thus affecting the clinical efficacy.In 2018,the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized clinical experts involving in management of side effects of GIST targeted drugs,based on clinical evidences and experiences,to formulate the first of Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.With the popularization of clinical application of TKIs and the deepening understanding of their side effects,especially the new type of TKIs drugs added to drug pipeline of GIST in recent years,the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organize experts to revise,update and formulate the Chinese expert consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumor(2022 edition),in order to guide the early warning and treatment of TKIs-associated side effects in clinical practice.